arrow
M

Martin Janz

max delbrück center for molecular medicine
H指数:31
被引数:4,604

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition

MYC失调使癌细胞对N-肉豆蔻酰转移酶抑制更敏感。

2025-08-220
PREAI
Impact of cellular composition and T-cell senescence of mononuclear cell concentrates on the manufacturing process of chimeric antigen receptor (CAR) T-cells

单核细胞浓缩物中细胞组成和T细胞衰老对嵌合抗原受体(CAR)T细胞制备过程的影响

2025-07-290
OA
A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma
2024-01-010
PRE
Transcriptional reprogramming by mutated IRF4 in lymphoma

淋巴瘤中突变IRF4的转录重编程

2023-11-071
OAAI
Broadening the phenotypic and molecular spectrum of FINCA syndrome: Biallelic NHLRC2 variants in 15 novel individuals
2023-05-155
OAAI
Dysregulation of MYC-family proteins sensitizes cancers to NMT inhibition: identification of NMTi sensitivity and mechanism
2023-04-040
PRE
SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
2023-02-1611
OAAI
A multimorphic mutation in IRF4 causes human autosomal dominant combined immunodeficiency
2023-01-1313
PRE
Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase KDM4C in B-cell lymphomas
2022-04-284
OAAI
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
2022-02-17302
OA
Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma
2021-09-2228
OAAI
PDGFA-associated protein 1 protects mature B lymphocytes from stress-induced cell death and promotes antibody gene diversification
2020-07-019
OAAI
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma (vol 32, pg 861, 2020)
2020-06-230
OAAI
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (vol 45, pg 810, 2020)
2020-05-310
OAAI